DDrare: Database of Drug Development for Rare Diseases

2'-fucosyllactose (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease [ 2,209 clinical trials, 1,276 drugs, (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03847467 (ClinicalTrials.gov)	September 20, 2019	12/2/2019	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in Pediatric and Young Adult IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Drug: 2'-Fucosyllactose;Other: Placebo	Children's Hospital Medical Center, Cincinnati	Broad Institute;University of Cincinnati;Connecticut Children's Medical Center	Recruiting	11 Years	25 Years	All	216	Phase 1;Phase 2	United States

97. Ulcerative colitis [ 2,269 clinical trials, 1,331 drugs, (DrugBank: 241 drugs), 114 drug target genes, 181 drug target pathways]

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,269 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03847467 (ClinicalTrials.gov)	September 20, 2019	12/2/2019	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in Pediatric and Young Adult IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Drug: 2'-Fucosyllactose;Other: Placebo	Children's Hospital Medical Center, Cincinnati	Broad Institute;University of Cincinnati;Connecticut Children's Medical Center	Recruiting	11 Years	25 Years	All	216	Phase 1;Phase 2	United States